Quantitative analysis of plasma DNA in anal cancer patients

Ewa Małusecka; Monika Giglok; Rafał Suwiński; Tomasz Rutkowski; Agnieszka Mazurek

doi:10.5114/wo.2022.118132

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2022
vol. 26

Send email

Copy url:

abstract:

Original paper

Quantitative analysis of plasma DNA in anal cancer patients

Ewa Małusecka

¹

,

Monika Giglok

²

,

Rafał Suwiński

²

,

Tomasz Wojciech Rutkowski

³

,

Agnieszka Maria Mazurek

¹

Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska- Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland
Radiotherapy Clinic and Teaching Hospital, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland
Ist Radiation and Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland

Contemp Oncol (Pozn) 2022; 26 (2): 128–132

DOI: https://doi.org/10.5114/wo.2022.118132

Online publish date: 2022/06/30

View full text Get citation

PlumX metrics:

Introduction
The availability and non-invasiveness of circulating cell-free DNA (cfDNA) opens up new possibilities for real-time serial testing. The relationship between cfDNA concentration, clinical factors and suitability for monitoring was analyzed in patients with newly diagnosed anal squamous cell carcinoma (ASCC).

Material and methods
Blood samples were collected at several points during and after treatment. Patients were homogeneously treated with chemoradiotherapy.

Results
The concentration of cfDNA strongly correlated with the tumor volume (r = 0.9, p = 0.00006) and number of neutrophils (r = 0.706, p = 0.0069). Monitoring of cfDNA levels during treatment showed an increase after initiation of therapy, a peak at the end of treatment with significantly higher values for advanced than in T1/T2 tumors, and a decrease (T3/T4) during follow-up. However, neither the concentration of cfDNA before treatment nor its changes correlated with the response to chemoradiotherapy. There was no association between baseline cfDNA levels and T, N, age and gender.

Conclusions
Substantial changes in plasma cfDNA content can be observed after chemoradiotherapy for ASCC. However, the small number of cases studied makes it difficult to assess the usefulness of the cfDNA test.

keywords:

Quantitative analysis of plasma DNA in anal cancer patients

Ewa Małusecka 1 , Monika Giglok 2 , Rafał Suwiński 2 , Tomasz Wojciech Rutkowski 3 , Agnieszka Maria Mazurek 1

plasma, radiochemotherapy, anal cancer, circulating cell-free DNA

Ewa Małusecka

¹

,

Monika Giglok

²

,

Rafał Suwiński

²

,

Tomasz Wojciech Rutkowski

³

,

Agnieszka Maria Mazurek

¹